vs
Amneal Pharmaceuticals, Inc.（AMRX）与美泰（MAT）财务数据对比。点击上方公司名可切换其他公司
美泰的季度营收约是Amneal Pharmaceuticals, Inc.的1.2倍（$862.2M vs $722.5M），Amneal Pharmaceuticals, Inc.净利率更高（10.8% vs 7.1%，领先3.7%），美泰同比增速更快（4.3% vs 3.9%），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（1.5% vs -10.6%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
美泰是美国知名玩具及娱乐企业，旗下影视制作部门美泰影业运营时间为2018年9月6日至2025年6月2日。其前身为2013年10月16日成立的美泰Playground Productions，更早可追溯至美泰娱乐、美泰工作室等集团原有娱乐业务品牌。
AMRX vs MAT — 直观对比
营收规模更大
MAT
是对方的1.2倍
$722.5M
营收增速更快
MAT
高出0.4%
3.9%
净利率更高
AMRX
高出3.7%
7.1%
两年增速更快
AMRX
近两年复合增速
-10.6%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $722.5M | $862.2M |
| 净利润 | $78.0M | $61.0M |
| 毛利率 | 44.3% | 44.9% |
| 营业利润率 | — | — |
| 净利率 | 10.8% | 7.1% |
| 营收同比 | 3.9% | 4.3% |
| 净利润同比 | 217.0% | 251.4% |
| 每股收益（稀释后） | $0.19 | $0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXMAT
| Q1 26 | $722.5M | $862.2M | ||
| Q4 25 | $814.3M | $1.8B | ||
| Q3 25 | $784.5M | $1.7B | ||
| Q2 25 | $724.5M | $1.0B | ||
| Q1 25 | $695.4M | $826.6M | ||
| Q4 24 | $730.5M | $1.6B | ||
| Q3 24 | $702.5M | $1.8B | ||
| Q2 24 | $701.8M | $1.1B |
净利润AMRXMAT
| Q1 26 | $78.0M | $61.0M | ||
| Q4 25 | $35.1M | $106.2M | ||
| Q3 25 | $2.4M | $278.4M | ||
| Q2 25 | $22.4M | $53.4M | ||
| Q1 25 | $12.2M | $-40.3M | ||
| Q4 24 | $-31.1M | $140.9M | ||
| Q3 24 | $-156.0K | $372.4M | ||
| Q2 24 | $6.0M | $56.9M |
毛利率AMRXMAT
| Q1 26 | 44.3% | 44.9% | ||
| Q4 25 | 36.5% | 45.9% | ||
| Q3 25 | 34.9% | 50.0% | ||
| Q2 25 | 39.5% | 50.9% | ||
| Q1 25 | 36.8% | 49.4% | ||
| Q4 24 | 36.0% | 50.7% | ||
| Q3 24 | 38.4% | 53.1% | ||
| Q2 24 | 35.6% | 49.2% |
营业利润率AMRXMAT
| Q1 26 | — | — | ||
| Q4 25 | 13.8% | 8.0% | ||
| Q3 25 | 9.0% | 21.9% | ||
| Q2 25 | 15.4% | 7.7% | ||
| Q1 25 | 14.4% | -6.4% | ||
| Q4 24 | 10.4% | 9.6% | ||
| Q3 24 | 12.6% | 26.5% | ||
| Q2 24 | 13.6% | 7.7% |
净利率AMRXMAT
| Q1 26 | 10.8% | 7.1% | ||
| Q4 25 | 4.3% | 6.0% | ||
| Q3 25 | 0.3% | 16.0% | ||
| Q2 25 | 3.1% | 5.2% | ||
| Q1 25 | 1.8% | -4.9% | ||
| Q4 24 | -4.3% | 8.6% | ||
| Q3 24 | -0.0% | 20.2% | ||
| Q2 24 | 0.9% | 5.3% |
每股收益（稀释后）AMRXMAT
| Q1 26 | $0.19 | $0.20 | ||
| Q4 25 | $0.10 | $0.32 | ||
| Q3 25 | $0.01 | $0.88 | ||
| Q2 25 | $0.07 | $0.16 | ||
| Q1 25 | $0.04 | $-0.12 | ||
| Q4 24 | $-0.10 | $0.40 | ||
| Q3 24 | $0.00 | $1.09 | ||
| Q2 24 | $0.02 | $0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $866.0M |
| 总债务越低越好 | — | $2.3B |
| 股东权益账面价值 | — | $2.1B |
| 总资产 | — | $6.3B |
| 负债/权益比越低杠杆越低 | — | 1.11× |
8季度趋势，按日历期对齐
现金及短期投资AMRXMAT
| Q1 26 | — | $866.0M | ||
| Q4 25 | $282.0M | $1.2B | ||
| Q3 25 | $201.2M | $691.9M | ||
| Q2 25 | $71.5M | $870.5M | ||
| Q1 25 | $59.2M | $1.2B | ||
| Q4 24 | $110.6M | $1.4B | ||
| Q3 24 | $74.0M | $723.5M | ||
| Q2 24 | $43.8M | $722.4M |
总债务AMRXMAT
| Q1 26 | — | $2.3B | ||
| Q4 25 | $2.6B | $2.3B | ||
| Q3 25 | $2.6B | $2.3B | ||
| Q2 25 | $2.2B | $2.3B | ||
| Q1 25 | $2.2B | $2.3B | ||
| Q4 24 | $2.4B | $2.3B | ||
| Q3 24 | $2.4B | $2.3B | ||
| Q2 24 | $2.4B | $2.3B |
股东权益AMRXMAT
| Q1 26 | — | $2.1B | ||
| Q4 25 | $-70.8M | $2.2B | ||
| Q3 25 | $-109.5M | $2.3B | ||
| Q2 25 | $-112.1M | $2.2B | ||
| Q1 25 | $-131.7M | $2.1B | ||
| Q4 24 | $-109.3M | $2.3B | ||
| Q3 24 | $-93.4M | $2.3B | ||
| Q2 24 | $-57.5M | $2.0B |
总资产AMRXMAT
| Q1 26 | — | $6.3B | ||
| Q4 25 | $3.7B | $6.6B | ||
| Q3 25 | $3.6B | $6.6B | ||
| Q2 25 | $3.4B | $6.2B | ||
| Q1 25 | $3.4B | $6.2B | ||
| Q4 24 | $3.5B | $6.5B | ||
| Q3 24 | $3.5B | $6.5B | ||
| Q2 24 | $3.5B | $5.9B |
负债/权益比AMRXMAT
| Q1 26 | — | 1.11× | ||
| Q4 25 | — | 1.04× | ||
| Q3 25 | — | 1.03× | ||
| Q2 25 | — | 1.08× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.03× | ||
| Q3 24 | — | 1.01× | ||
| Q2 24 | — | 1.18× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | — |
| 自由现金流经营现金流 - 资本支出 | — | $-88.1M |
| 自由现金流率自由现金流/营收 | — | -10.2% |
| 资本支出强度资本支出/营收 | — | 7.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AMRXMAT
| Q1 26 | — | — | ||
| Q4 25 | $130.3M | $796.6M | ||
| Q3 25 | $118.5M | $72.0M | ||
| Q2 25 | $83.8M | $-300.1M | ||
| Q1 25 | $7.4M | $24.8M | ||
| Q4 24 | $118.1M | $862.1M | ||
| Q3 24 | $141.8M | $155.8M | ||
| Q2 24 | $39.7M | $-252.9M |
自由现金流AMRXMAT
| Q1 26 | — | $-88.1M | ||
| Q4 25 | $108.5M | — | ||
| Q3 25 | $106.2M | — | ||
| Q2 25 | $61.0M | — | ||
| Q1 25 | $-5.8M | — | ||
| Q4 24 | $102.9M | — | ||
| Q3 24 | $124.8M | — | ||
| Q2 24 | $29.0M | — |
自由现金流率AMRXMAT
| Q1 26 | — | -10.2% | ||
| Q4 25 | 13.3% | — | ||
| Q3 25 | 13.5% | — | ||
| Q2 25 | 8.4% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 17.8% | — | ||
| Q2 24 | 4.1% | — |
资本支出强度AMRXMAT
| Q1 26 | — | 7.6% | ||
| Q4 25 | 2.7% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.5% | — |
现金转化率AMRXMAT
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | 7.50× | ||
| Q3 25 | 50.00× | 0.26× | ||
| Q2 25 | 3.74× | -5.62× | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | 6.12× | ||
| Q3 24 | — | 0.42× | ||
| Q2 24 | 6.62× | -4.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
MAT
暂无分部数据
